AstraZeneca

Open: 69.28 Close: 68.91 Change: -0.37

Our AI found unexpected things about AstraZeneca Stock.

How much time have you spent trying to decide whether investing in AstraZeneca? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, company, …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

Shares of AstraZeneca PLC AZN, +1.21% advanced 1.21%, £109.02, £14.90 short of its 52-week high (£123.92) The FTSE 100 Index UKX, -0.13% fell 0.13%, £12.99% to 7,683.

Today's News

Shares of AstraZeneca PLC AZN, +1.21% advanced 1.21%, £109.02, £14.90 short of its 52-week high (£123.92), which the company reached on April 18. The FTSE 100 Index UKX, -0.13% fell 0.13%, £12.99% to 7,683.96 Tuesday. AstraZeneca was looking to reimagine financial controls compliance with the help of the right enterprise technology to drive better performance. Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer. Compugen is entitled to receive a $10 million milestone payment from Astra. AstraZeneca is an agile, fast-moving and emerging industry leader in oncology. In 2022, revenue was $44.35 billion, an increase of 18.53%. AstraZeneca will present new clinical and real-world data in multiple hematological conditions at the 65th American Society of Hematology (ASH) Annual Meeting andExp... astrazeneca.in company profile & executives - Astra. Astrazeneca PLC is a science-led biopharmaceutical company. Astrazenecas purchases of Gracell for up to $1.2 billion (of which $1 billion is upfront), and Icosavax for approximately $1.1 billion ( of which $838 million is upfront) Astrazenca currently features a Zacks Rank of #3. AstraZeneca to buy Icosavax for $1.1B. Astra has signed a collaboration agreement with biotechnology company Omniose to research vaccines for serious bacterial diseases.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

This document will help you to evaluate AstraZeneca without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, company, Astra, PLC, Compugen, upfront, Icosavax, and the most common words in the summary are: astrazeneca, best, news, credit, market, gracell, company, . One of the sentences in the summary was: Shares of AstraZeneca PLC AZN, +1.21% advanced 1.21%, £109.02, £14.90 short of its 52-week high (£123.92) The FTSE 100 Index UKX, -0.13% fell 0.13%, £12.99% to 7,683.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #best #news #credit #market #gracell #company.